ORGANOGENESIS HOLDINGS INC. Restricted Cash and Cash Equivalents
ORGANOGENESIS HOLDINGS INC. (ORGO) had Restricted Cash and Cash Equivalents of $312.50 million as of 2017-12-31, per its 10-K filed 2018-03-14.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2018-03-14
- 2017-12-31: Restricted Cash and Cash Equivalents $312.50M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2017-12-31 | $312.50M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |